228 related articles for article (PubMed ID: 26028645)
1. Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA.
Wallerek S; Sørensen JB
Eur Respir Rev; 2015 Jun; 24(136):340-55. PubMed ID: 26028645
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
Pierceall WE; Olaussen KA; Rousseau V; Brambilla E; Sprott KM; Andre F; Pignon JP; Le Chevalier T; Pirker R; Jiang C; Filipits M; Chen Y; Kutok JL; Weaver DT; Ward BE; Soria JC
Ann Oncol; 2012 Sep; 23(9):2245-2252. PubMed ID: 22269178
[TBL] [Abstract][Full Text] [Related]
3. Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy.
Bergot E; Levallet G; Campbell K; Dubois F; Lechapt E; Zalcman G
Eur Respir Rev; 2013 Dec; 22(130):565-76. PubMed ID: 24293473
[TBL] [Abstract][Full Text] [Related]
4. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Leng XF; Chen MW; Xian L; Dai L; Ma GY; Li MH
J Exp Clin Cancer Res; 2012 Mar; 31(1):25. PubMed ID: 22439756
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
[TBL] [Abstract][Full Text] [Related]
6. 16th World Conference on Lung Cancer.
Landman A
Lancet Oncol; 2015 Oct; 16(13):1290. PubMed ID: 26387750
[No Abstract] [Full Text] [Related]
7. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Lafuente-Sanchis A; Zúñiga Á; Galbis JM; Cremades A; Estors M; Martínez-Hernández NJ; Carretero J
Clin Transl Oncol; 2016 Aug; 18(8):798-804. PubMed ID: 26542178
[TBL] [Abstract][Full Text] [Related]
8. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy.
Zou ZQ; Du YY; Sui G; Xu SN
Asian Pac J Cancer Prev; 2015; 16(8):3189-94. PubMed ID: 25921119
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
10. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis.
Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
Mol Biol Rep; 2012 Jun; 39(6):6933-42. PubMed ID: 22302397
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
12. Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.
Ikeda N; Nagase S; Ohira T
Ann Thorac Cardiovasc Surg; 2009 Jun; 15(3):144-9. PubMed ID: 19597387
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
[TBL] [Abstract][Full Text] [Related]
14. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
Zhang J; Chen N; Qi J; Zhou B; Qiu X
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma.
Voortman J; Goto A; Mendiboure J; Sohn JJ; Schetter AJ; Saito M; Dunant A; Pham TC; Petrini I; Lee A; Khan MA; Hainaut P; Pignon JP; Brambilla E; Popper HH; Filipits M; Harris CC; Giaccone G
Cancer Res; 2010 Nov; 70(21):8288-98. PubMed ID: 20978195
[TBL] [Abstract][Full Text] [Related]
17. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
Xu YP; Li B; Xu XL; Mao WM
Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
[TBL] [Abstract][Full Text] [Related]
18. Video-assisted thoracoscopic lobectomy mitigates adverse oncological effects of delayed adjuvant chemotherapy for nonsmall cell lung cancer patients.
Jing X; Lin Y; Zhang B; Zhang G
J BUON; 2016; 21(6):1524-1529. PubMed ID: 28039718
[TBL] [Abstract][Full Text] [Related]
19. Molecular Markers for Long-term Survival in Stage IIIA (N2) NSCLC Patients.
Nastase A; Dima SO; Lupo A; Laszlo V; Tagett R; Draghici S; Georgescu ME; Nechifor A; Berbece S; Popescu I; Alifano M; Klepetko W; Grigoroiu M
Cancer Genomics Proteomics; 2022; 19(1):94-104. PubMed ID: 34949662
[TBL] [Abstract][Full Text] [Related]
20. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
